Skip to main content

This website contains promotional content and is intended for Healthcare Professionals based in the United Kingdom only. Some content may only be relevant to HCPs practising in Great Britain (England, Scotland and Wales) according to product availability. This website is optimised for desktop use, and some features may perform differently on mobile devices.

Adverse event reporting can be found at the bottom of the page.

  1. Article
  2. Source: Campus Sanofi
  3. 17 Mar 2026

Praluent® (alirocumab) Administration

Author: Sanofi

Editorial Team

Praluent logo

Prescribing Information (UK)

Praluent® can be injected subcutaneously into the thigh, abdomen or upper arm. Patients should rotate the injection site with each injection.1

Praluent Image

Download the below leaflet to read how to administer Praluent

Download

Watch this video to see how to administer Praluent

SEE MORE FROM SCIENCE

Praluent®

Find more information on Indication, Administration and Mechanism of Action and watch videos about Praluent®.

Patient Website

Find resources and support for your patients on Praluent®. Find useful links about how patients can manage their cholesterol.

Get in touch with the Dyslipidaemia Team
MAT-XU-2201545 (v5.0) Date of Preparation: October 2023
References
  1. Praluent (alirocumab). Summary of Product Characteristics, Sanofi. 2025.
  2. Frias JP, Koren MJ, Loizeau V, et al. The SYDNEY Device Study: A Multicenter, Randomized, Open-label Usability Study of a 2-mL Alirocumab Autoinjector Device. Clinical Therapeutics. 2020; 42(1):94-107.
  3. Praluent (alirocumab) Patient Information Leaflet, 150mg. Sanofi, 2026.
  4. Praluent (alirocumab) Patient Information Leaflet, 300mg. Sanofi, 2026.
  5. Tatlock S, et al. Value Health 2017;20:430–440.
  6. Roth E, et al. Clin Ther 2015;37(9):1945–1954.

MAT-XU-2503036 (v2.0) Date of Preparation: March 2026  

Related Content

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to the Sanofi drug safety department on Tel: +44 (0) 800 0902 314. Alternatively, send via email to UK-drugsafety@sanofi.com
Back to top
Privacy Notice Update | We have updated our Privacy Notice for Healthcare Professionals to improve your experience collaborating with us, maintain high standards of privacy and ultimately strengthen the trust you place in us. Key improvements include enhanced clarity on why and how Sanofi processes your personal data.
Staying in TouchTerms of UseCookie PolicySitemapAccessibility Statement

© Sanofi 2026. All rights reserved.

MAT-XU-2300297 (v8.0) - Date of Preparation: December 2025

Privacy Notice Update | We have updated our Privacy Notice for Healthcare Professionals to improve your experience collaborating with us, maintain high standards of privacy and ultimately strengthen the trust you place in us. Key improvements include enhanced clarity on why and how Sanofi processes your personal data.
Staying in TouchTerms of UseCookie PolicySitemapAccessibility Statement
Back to top

© Sanofi 2026. All rights reserved.

MAT-XU-2300297 (v8.0) - Date of Preparation: December 2025